logo
logo

501.0575 Weight-Loss Consumer Bill of Rights

(1) The Weight-Loss Consumer Bill of Rights shall consist of the following provisions:

(A) WARNING: RAPID WEIGHT LOSS MAY CAUSE SERIOUS HEALTH PROBLEMS. RAPID WEIGHT LOSS IS WEIGHT LOSS OF MORE THAN 11/2 POUNDS TO 2 POUNDS PER WEEK OR WEIGHT LOSS OF MORE THAN 1 PERCENT OF BODY WEIGHT PER WEEK AFTER THE SECOND WEEK OF PARTICIPATION IN A WEIGHT-LOSS PROGRAM.

(B) CONSULT YOUR PERSONAL PHYSICIAN BEFORE STARTING ANY WEIGHT-LOSS PROGRAM.

(C) ONLY PERMANENT LIFESTYLE CHANGES, SUCH AS MAKING HEALTHFUL FOOD CHOICES AND INCREASING PHYSICAL ACTIVITY, PROMOTE LONG-TERM WEIGHT LOSS.

(D) QUALIFICATIONS OF THIS PROVIDER ARE AVAILABLE UPON REQUEST.

(E) YOU HAVE A RIGHT TO:

  1. ASK QUESTIONS ABOUT THE POTENTIAL HEALTH RISKS OF THIS PROGRAM AND ITS NUTRITIONAL CONTENT, PSYCHOLOGICAL SUPPORT, AND EDUCATIONAL COMPONENTS.
  2. RECEIVE AN ITEMIZED STATEMENT OF THE ACTUAL OR ESTIMATED PRICE OF THE WEIGHT-LOSS PROGRAM, INCLUDING EXTRA PRODUCTS, SERVICES, SUPPLEMENTS, EXAMINATIONS, AND LABORATORY TESTS.
  3. KNOW THE ACTUAL OR ESTIMATED DURATION OF THE PROGRAM.
  4. KNOW THE NAME, ADDRESS, AND QUALIFICATIONS OF THE DIETITIAN OR NUTRITIONIST WHO HAS REVIEWED AND APPROVED THE WEIGHT-LOSS PROGRAM ACCORDING TO s. 468.505(1)(j), FLORIDA STATUTES.

(2) The copies of the Weight-Loss Consumer Bill of Rights to be posted according to s. 501.0573(6) shall be printed in at least 24-point boldfaced type on one side of a sign. The palm-sized copies to be distributed according to s. 501.0573(5) shall be in boldfaced type and legible. Each weight-loss provider shall be responsible for producing and printing appropriate copies of the Weight-Loss Consumer Bill of Rights.History.—s. 4, ch. 93-274; s. 45, ch. 2000-154.https://www.flsenate.gov/Laws/Statutes/2015/501.0575

MEDVi money back guarantee

Free, expedited delivery

Doctor-led plans & coaching

No hidden fees

help@medvi.org
(323) 690-1564
131 Continental Dr. Ste 305, Newark, DE 19713
<

*The assessment made available on the MEDVi website does not create a doctor-patient relationship between the individual completing the assessment and MEDVi. OpenLoop Health, a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to determine if an individual does not qualify for GLP-1s. The answers an individual provides to the MEDVi assessment consequently determine if the individual is screened out of eligibility for GLP-1 medication, and an OpenLoop Health clinician will meet with an individual after checkout to determine if they qualify for a prescription. OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients.
All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results from compounded medications found on the MEDVi platform may vary and be affected by an individual's adherence to the program and their clinician's recommendations. Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, which is informed by a telehealth consultation and medical history.
We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. MEDVi does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.

Pharmacy Providers

We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies to discuss any product shortages, shipping delays, and get updated reports on their medication testing.

*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. MEDVi patients typically result in 1-2 lbs per week weight loss after 4 weeks, involving a healthy diet and exercise changes.
Consult a healthcare professional before using medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

Medication is included in the cost of the MEDVi Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy® ,Ozempic®), and products displayed on this Internet site are protected and belong to their respetive owners. Medical treatment is provided by “CareGLP Affiliated P.C.s,” and OpenLoop Health, affiliated networks for medical professional corporations and associations.

© 2025 MEDVi. All rights reserved

  • Terms & Conditions
  • Privacy Policy
  • Privacy Practices
  • Medical Consent
  • For California Residents
  • Bill of Rights